Skip to main content
EVHEvolent Health, IncSell4.5·$5.74+0.53%
SellModerate Confidence
Investment thesis

Evolent Health is in an early technical recovery from a deep drawdown, but a quality-floor breach, a negative asymmetry gate after already hitting its target, and an inconsistent earnings history keep the setup on exit watch.

Thesis pillars

  • Quality Floor BreachStable
  • Negative Asymmetry Target ReachedStable
  • Deep Drawdown Recovery SetupStable
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Evolent Health, Inc (EVH) Stock Analysis

Recovery setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Health Information Services

Sell if holding. Engine safety override at $5.74: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 13%; Below-average business quality.

Evolent Health provides specialty care management and administrative services to health plans and other risk-bearing payers, concentrating on oncology, cardiology, and musculoskeletal conditions through its New Century Health platform and the Identifi value-based care... Read more

$5.74+2.6% A.UpsideScore 4.5/10#21 of 24 Health Information Services
QualityF-score4 / 9FCF yield8.24%
Stop $5.34Target $5.89(resistance)A.R:R -0.7:1
Analyst target$5.88+2.5%13 analysts
$5.89our TP
$5.74price
$5.88mean
$3
$8

Sell if holding. Engine safety override at $5.74: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 70. Score 4.5/10, moderate confidence.

Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-06

Recent Developments — Evolent Health, Inc

Generated 2026-07-07T11:31:43Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 202631d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Target reached (-10.8% upside)
Quality below floor (1.6 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)14.8
Mkt Cap$642M
EV/EBITDA20.0
Profit Mgn-26.3%
ROE-65.1%
Rev Growth2.6%
Beta0.77
DividendNone
Rating analysts20

Quality Signals

Piotroski F4/9

Options Flow

P/C0.33bullish
IV97%elevated
Max Pain$3-56.4% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerMolina Healthcare26%
    10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'
  • LOWCustomerCook County Health and Hospitals System16%
    10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'
  • LOWCustomerFlorida Blue14%
    10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'
  • LOWCustomerCentene Corporation12%
    10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers

Unprofitable operations — net margin -26.3%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Moat
3.1
Piotroski F
4.4
Current Ratio
5.0
No competitive moatQuality concerns

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Bollinger
1.1
Support Resistance
1.4
Gap
6.0

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.3
Growth Rank
2.1
Value Rank
9.6

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
News Activity
5.0
Earnings concerns: 2B/2M
GatesA.R:R -0.7=NEGATIVEDeath cross (50MA < 200MA)Momentum 4.9<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.9>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 31d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Speculative
RSI
70 · Overbought
20D MA 50D MA 200D MADEATH CROSSSupport $4.13Resistance $6.01

Price Targets

$5
$6
A.Upside+2.6%
A.R:R-0.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-10.8% upside)
! Quality below floor (1.6 < 4.0)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-06 (31d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is EVH stock a buy right now?

Sell if holding. Engine safety override at $5.74: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 70. Prior stop was $5.34. Score 4.5/10, moderate confidence.

What is the EVH stock price target?

Take-profit target: $5.89 (+2.6% upside). Prior stop was $5.34. Stop-loss: $5.34.

What are the risks of investing in EVH?

Target reached (-10.8% upside); Quality below floor (1.6 < 4.0).

Is EVH overvalued or undervalued?

Evolent Health, Inc trades at a P/E of N/A (forward 14.8). TrendMatrix value score: 6.2/10. Verdict: Sell.

What do analysts say about EVH?

20 analysts cover EVH with a consensus score of 4.2/5. Average price target: $6.

What does Evolent Health, Inc do?Evolent Health provides specialty care management and administrative services to health plans and other risk-bearing...

Evolent Health provides specialty care management and administrative services to health plans and other risk-bearing payers, concentrating on oncology, cardiology, and musculoskeletal conditions through its New Century Health platform and the Identifi value-based care technology. The company is paid largely on a per-member-per-month basis, including capitated Performance Suite arrangements where it assumes medical cost risk. Its four largest partners — Molina Healthcare, Cook County Health and Hospitals System, Florida Blue, and Centene Corporation — comprised 25.7%, 16.4%, 14.2%, and 12.2%, r

Related stocks: WAY (Waystar Holding Corp.) · OMDA (Omada Health, Inc.) · WEAV (Weave Communications, Inc.) · PRVA (Privia Health Group, Inc.) · NRC (NRC Health)
Home Stocks EVH

Latest news

Latest News

Benzinga7d ago